🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

82 results for “Chen” Clear

  1. Ataluren

    PTC THERAPEUTICS, INC.

    Muscular Dystrophy, Duchenne

    phase 3 small molecule terminated

    3 trials

  2. Ataluren

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    9 trials

  3. Bisoprolol Fumarate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  4. CASIMERSEN (SRP-4045), GOLODIRSEN (SRP-4053), 0,9% sodium chloride

    Sarepta Therapeutics

    Patients with Duchenne Muscular Dystrophy Amenable to Exon 45 or 53 Skipping.

    phase 3 small molecule active

    1 trial

  5. Casimersen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule terminated

    1 trial

  6. Coenzyme Q10 and Lisinopril

    United Therapeutics Europe Ltd

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  7. Deflazacort

    PTC THERAPEUTICS, INC.

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    3 trials

  8. Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  9. Dupilumab

    Regeneron UK Limited

    Lichen Simplex Chronicus

    phase 3 small molecule active

    2 trials

  10. ETEPLIRSEN (AVI-4658)

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  11. Eteplirsen

    Sarepta Therapeutics

    Muscular Dystrophy, Duchenne

    phase 3 small molecule active

    2 trials

  12. Fordadistrogene Movaparvovec, ECULIZUMAB, Placebo for PF-06939926

    Pfizer Australia Pty Ltd

    DUCHENNE MUSCULAR DYSTROPHY (DMD)

    phase 3 small molecule active

    1 trial

  13. ITF2357

    Italfarmaco S.p.A.

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  14. Loperamide

    Chengdu University of Traditional Chinese Medicine

    Diarrhea-predominant Irritable Bowel Syndrome

    phase 3 small molecule completed

    1 trial

  15. PLACEBO for GIVINOSTAT hydrochloride monohydrate (ITF2357) 10 mg/mL oral suspension, ITF2357

    Italfarmaco S.p.A.

    Duchenne muscular dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  16. RO7239361

    Hoffmann-La Roche

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  17. SGT-003

    Solid Biosciences

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    2 trials

  18. SRP-4045

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    2 trials

  19. Saline, 0.9% sodium chloride solution IV infusion marketed authorized will be used as the placebo and will be supplied by the site. the SmPC previously authorized are Country specific. for Belgium, Spain and Sweden per local requirements under CTDs no SmPCs were submitted., Delandistrogene moxeparvovec-rokl

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 small molecule active

    1 trial

  20. Viltolarsen

    Lacuna Pharma Pty Ltd

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule active

    1 trial

  21. delandistrogene moxeparvovec

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy

    phase 3 gene therapy active

    7 trials

  22. eteplirsen

    Sarepta Therapeutics

    Duchenne Muscular Dystrophy (DMD)

    phase 3 small molecule completed

    2 trials

  23. prednisone

    Ultragenyx UK Limited

    Duchenne Muscular Dystrophy

    phase 3 small molecule completed

    1 trial

  24. A Phase 1/2, Multicenter, Open-Label Study to Investigate the Safety, Tolerability, and Efficacy of a Single Intravenous Dose of SGT-003 in Males with Duchenne Muscular Dystrophy

    Solid Biosciences

    Duchenne muscular dystrophy

    phase 2 other active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources